Zobrazeno 1 - 10
of 529
pro vyhledávání: '"Arinobu Tojo"'
Autor:
Akiko M Saito, Hiroya Hashimoto, Takehiko Doi, Arinobu Tojo, Hirokazu Kanegane, Hisanori Fujino, Aki Sato, Keizo Horibe, Yuta Kawahara, Yozo Nakazawa, Atsuko Nakazawa, Rintaro Ono, Kenichi Sakamoto, Ko Kudo, Kazuko Kudo, Ryu Yanagisawa, Toyotaka Kawamata, Osamu Miyazaki, Yasunori Ota, Atsushi Manabe, Kensuke Usuki, Hitoshi Kiyoi, Akira Morimoto, Yoko Shioda
Publikováno v:
BMJ Open, Vol 14, Iss 6 (2024)
Introduction Although the prognosis of Langerhans cell histiocytosis (LCH) is excellent, the high recurrence rate and permanent consequences, such as central diabetes insipidus and LCH-associated neurodegenerative diseases, remain to be resolved. Bas
Externí odkaz:
https://doaj.org/article/615a8073dc1d44bab10f21cc6cbe0dab
Autor:
Sohsuke Meshitsuka, Ryo Ninomiya, Tokiko Nagamura-Inoue, Takashi Okada, Muneyoshi Futami, Arinobu Tojo
Publikováno v:
Regenerative Therapy, Vol 21, Iss , Pp 442-452 (2022)
Introduction: Mesenchymal stromal cells (MSCs) hold the potential for application as cellular therapy products; however, there are many problems that need to be addressed before the use in clinical settings, these include the heterogeneity of MSCs, s
Externí odkaz:
https://doaj.org/article/23b9bdd802e2484993f3745bd0c5e6cd
Autor:
Yuji Okamoto, Mitsuhito Hirano, Kai Morino, Masashi K. Kajita, Shinji Nakaoka, Mayuko Tsuda, Kei-ji Sugimoto, Shigehisa Tamaki, Junichi Hisatake, Hisayuki Yokoyama, Tadahiko Igarashi, Atsushi Shinagawa, Takeaki Sugawara, Satoru Hara, Kazuhisa Fujikawa, Seiichi Shimizu, Toshiaki Yujiri, Hisashi Wakita, Kaichi Nishiwaki, Arinobu Tojo, Kazuyuki Aihara
Publikováno v:
npj Systems Biology and Applications, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the BCR-ABL1 tyrosine kinase. Although ABL1-specific tyrosine kinase inhibitors (TKIs) including nilotinib have dramatically improved the prognosis of patients with CM
Externí odkaz:
https://doaj.org/article/58f4e055c3eb45ed81510406b1170155
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-12 (2022)
Abstract Even though hematopoietic stem cell transplantation (HSCT) allows successful treatment for many malignant and non-malignant disorders, its curative potential remains limited by severe side effects, including infections and other transplant-r
Externí odkaz:
https://doaj.org/article/d0de852792fe4aa7a93ec2501a565217
Autor:
Shintaro Kazama, Kazuaki Yokoyama, Toshimitsu Ueki, Hiroko Kazumoto, Hidetoshi Satomi, Masahiko Sumi, Ichiro Ito, Nozomi Yusa, Rika Kasajima, Eigo Shimizu, Rui Yamaguchi, Seiya Imoto, Satoru Miyano, Yukihisa Tanaka, Tamami Denda, Yasunori Ota, Arinobu Tojo, Hikaru Kobayashi
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Langerhans cell histiocytosis (LCH) and acute myeloid leukemia (AML) are distinct entities of blood neoplasms, and the exact developmental origin of both neoplasms are considered be heterogenous among patients. However, reports of concurrent LCH and
Externí odkaz:
https://doaj.org/article/343b5391b79e4685a836d62171caa319
Autor:
Mitsuhito Hirano, Yoichi Imai, Yuta Kaito, Takahiko Murayama, Kota Sato, Tadao Ishida, Junichi Yamamoto, Takumi Ito, Muneyoshi Futami, Masaki Ri, Hiroshi Yasui, Tamami Denda, Yukihisa Tanaka, Yasunori Ota, Masanori Nojima, Yasuhiko Kamikubo, Noriko Gotoh, Shinsuke Iida, Hiroshi Handa, Arinobu Tojo
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-19 (2021)
Abstract Background Multiple myeloma (MM) is an incurable disease. The acquisition of resistance to drugs, including immunomodulatory drugs (IMiDs), has a negative effect on its prognosis. Cereblon (CRBN) is a key mediator of the bioactivities of IMi
Externí odkaz:
https://doaj.org/article/f2e71599d7d641fb9ece99c28c22cc0d
Autor:
Reina Takeda, Kazuaki Yokoyama, Tomofusa Fukuyama, Toyotaka Kawamata, Mika Ito, Nozomi Yusa, Rika Kasajima, Eigo Shimizu, Nobuhiro Ohno, Kaoru Uchimaru, Rui Yamaguchi, Seiya Imoto, Satoru Miyano, Arinobu Tojo
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Lineage switches in acute leukemia occur rarely, and the underlying mechanisms are poorly understood. Herein, we report the case of an elderly patient with leukemia in which the leukemia started as B-cell acute lymphoblastic leukemia (B-ALL) and late
Externí odkaz:
https://doaj.org/article/ba95563bc5764258bbe66313ae81e65b
Autor:
Kaichi Nishiwaki, Kei‐ji Sugimoto, Shigehisa Tamaki, Junichi Hisatake, Hisayuki Yokoyama, Tadahiko Igarashi, Atsushi Shinagawa, Takeaki Sugawara, Satoru Hara, Kazuhisa Fujikawa, Seiichi Shimizu, Toshiaki Yujiri, Arinobu Tojo, Hisashi Wakita
Publikováno v:
Cancer Medicine, Vol 9, Iss 11, Pp 3742-3751 (2020)
Abstract For patients who have chronic myeloid leukemia (CML), one of the primary treatment options is administration of nilotinib 300 mg twice daily (BID). In previous studies which compared outcomes associated with nilotinib or imatinib treatment,
Externí odkaz:
https://doaj.org/article/d6cec3dbf9054fe0b643aba4e9c79cd9
Autor:
Naohi Sahara, Kazuaki Yokoyama, Takashi Matsunaga, Shinsuke Kitahara, Tomoki Fujii, Seiichiro Kobayashi, Nozomi Yusa, Eigo Shimizu, Seiya Imoto, Arinobu Tojo, Nobuhiro Ohno
Publikováno v:
Leukemia Research Reports, Vol 18, Iss , Pp 100348- (2022)
Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm (MPN) characterized by sustained mature neutrophilic leukocytosis. Recently, presence of colony-stimulating factor 3 receptor (CSF3R) mutations has been added to the diagnostic
Externí odkaz:
https://doaj.org/article/f6fd42615b3646b994dfdfe6b946e9f1
Autor:
Hideaki Kagami, Minoru Inoue, Hideki Agata, Izumi Asahina, Tokiko Nagamura-Inoue, Masataka Taguri, Arinobu Tojo
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 24, p 7328 (2022)
(1) Objectives: The effect of cell-processing protocols on the clinical efficacy of bone tissue engineering is not well-known. To maximize efficacy, we optimized the cell-processing protocol for bone-marrow-derived mesenchymal stromal cells for bone
Externí odkaz:
https://doaj.org/article/e93cae92b8e843cfa0df595cf10c05c9